|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Harvard University’s Alfred Goldberg, Ph.D., Daniel Finley, Ph.D., and Randall King, M.D., Ph.D., Named Harvard University Scientific Co-Founders
5/5/2011 8:40:10 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Proteostasis Therapeutics announced today that it has named Alfred Goldberg, Ph.D., and Daniel Finley, Ph.D., both Professors of Cell Biology, and Randall King, M.D., Ph.D., Associate Professor of Cell Biology, all at Harvard Medical School, as company scientific co-founders. In addition, Drs. Goldberg and King join Dr. Finley as a member of the company’s Scientific Advisory Board. The three researchers are leaders in understanding the ubiquitin-proteasome pathway, an essential mechanism for protein clearance and a major component of the Proteostasis Network that regulates protein folding, trafficking, and clearance within cells to maintain protein homeostasis.
|
|
|
|
|
|
|
|
|
|
|